5.51

1.96% -0.11

After Hours: 5.50 -0.010 -0.18%

Aura Biosciences Inc (AURA)

Overview News Price History Option Chain Financials Why AURA Down? Discussions Forecast

Aura Biosciences Inc stock is traded at $5.51, with a volume of 138.19K. It is down -1.96% in the last 24 hours and up +8.68% over the past month. Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.

Previous Close:

$5.62

Open:

$5.61

24h Volume:

138.19K

Relative Volume:

0.73

Market Cap:

$349.90M

Revenue:

Net Income/Loss:

$-76.41M

P/E Ratio:

-2.8698

EPS:

-1.92

Net Cash Flow:

$-64.56M

1W Performance:

+2.80%

1M Performance:

+8.68%

6M Performance:

-20.61%

1Y Performance:

-30.43%

1-Day Range:

$5.26

$5.61

1-Week Range:

$5.26

$5.815

52-Week Range:

$4.345

$8.16

Aura Biosciences Inc Stock (AURA) Company Profile

Name

Aura Biosciences Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

(617)500-8864

Address

80 GUEST STREET, BOSTON

Employee

106

Twitter

Next Earnings Date

2025-03-24

Latest SEC Filings

AURA's Discussions on Twitter

Compare AURA vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AURA Aura Biosciences Inc	5.51	356.89M	0	-76.41M	-64.56M	-1.92
VRTX Vertex Pharmaceuticals Inc	465.02	117.03B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	783.65	82.35B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	833.54	51.64B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	308.48	42.58B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	346.42	38.87B	4.98B	69.60M	525.67M	0.5198

Aura Biosciences Inc Stock (AURA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-26-25	Resumed	Evercore ISI	Outperform
May-28-25	Resumed	H.C. Wainwright	Buy
Jul-25-24	Initiated	H.C. Wainwright	Buy
Jul-27-23	Initiated	Scotiabank	Sector Outperform
Apr-17-23	Resumed	BTIG Research	Buy
Jul-19-22	Initiated	JMP Securities	Mkt Outperform

View All

Aura Biosciences Inc Stock (AURA) Latest News

04:40 AM

Aug Big Picture: Can Aura Biosciences Inc benefit from deglobalizationQuarterly Earnings Summary & AI Driven Stock Price Forecasts - baoquankhu1.vn

04:40 AM

01:46 AM

Avoiding Lag: Real-Time Signals in (AURA) Movement - Stock Traders Daily

01:46 AM

Feb 05, 2026

Aura Biosciences, Inc. (NASDAQ:AURA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Feb 05, 2026

Feb 01, 2026

Discipline and Rules-Based Execution in AURA Response - Stock Traders Daily

Feb 01, 2026

Jan 31, 2026

Guidance Update: Can Aura Biosciences Inc deliver alphaTrade Entry Report & Free Technical Confirmation Trade Alerts - baoquankhu1.vn

Jan 31, 2026

Jan 30, 2026

Analysts Have Conflicting Sentiments on These Healthcare Companies: Intellia Therapeutics (NTLA) and Viridian Therapeutics (VRDN) - The Globe and Mail

Jan 30, 2026

Jan 29, 2026